Jon Gerry

Dr. Jon Gerry


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TSTrevor Silva
Trevor Silva
TYTomoko Yamazaki
Tomoko Yamazaki
JCJohn M. Creasy
John M. Creasy
JGJon Gerry
Jon Gerry
BZBinbin Zheng-Lin
Binbin Zheng-Lin
KYKristina Young
Kristina Young
Background/Objectives: The selection of neoadjuvant therapy for patients with non-metastatic pancreatic adenocarcinoma remains challenging. Methods: We performed a single-institution, retrospective analysis of 79 patients who underwent resection of their pancreatic adenocarcinoma after receiving neoadjuvant therapy. Clinical and pathologic data were collected. Tumor fibrosis was quantified using Masson’s trichrome staining, tumor-infiltrating lymphocytes (TIL) were evaluated by an AI-based analysis of whole-slide H&E images, and immune cell populations were quantified by multiplex immunohistochemistry. Correlation analyses were performed between neoadjuvant treatment regimen, tumor regression, immune phenotypes, and survival. Results: All patients received chemotherapy, 77% FOLFIRINOX and 23% Gemcitabine/nab-paclitaxel (Abraxane). Eighteen percent of patients went on to receive radiation. Tumor regression grade (TRG) correlated with the neoadjuvant regimen. A reduction in tumor markers and the baseline neutrophil-to-lymphocyte ratio (NLR) correlated with overall survival. Among patients with an NLR > 3.3, FOLFIRINOX conferred a survival benefit over Gemcitabine/nab-paclitaxel, and radiation trended towards improved survival. Radiation was associated with increased fibrosis and reduced infiltration of CD8+ and regulatory T cells (Tregs). Increased Tregs and PDL1+ stromal cells were associated with poor response to neoadjuvant therapy, and NLR > 3.3 correlated with increased Treg infiltration. Conclusions: Our data suggest that patients with a high baseline NLR may benefit from intensified neoadjuvant therapy with FOLFIRINOX and radiation. Combination immunotherapy targeting Tregs and the PD1/PDL1 axis may further improve outcomes.

1 August 2025 in ACG Case Reports Journal
Verified
Journal Article
Open access
JYJin Yun
Jin Yun
JGJon Gerry
Jon Gerry
MGMark Gibson
Mark Gibson
ASAjay Singhvi
Ajay Singhvi
Gastroduodenal artery aneurysms (GDAA) are a rare but potentially life-threatening vascular condition. They can vary in presentation from being found incidentally on imaging to devastating rupture. We describe a case of 2 gastroduodenal aneurysms causing obstructive jaundice and acute cholangitis in an elderly woman, which was treated with coil embolization.rupture. GDAA of any size should be highly considered for treatment given the high mortality of eventual rupture.